U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07806695) titled 'Islet Function in Gestational Diabetes' on Sept. 01.
Brief Summary: The purpose of this research is to understand how the function of the human pancreas changes during and after pregnancy.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Gestational Diabetes Mellitus
Intervention:
DRUG: Exendin 9-39
Exendin 9-39 will be administered during one postpartum study day as an intravenous infusion at 300 pmol/kg/min for 4 hours, beginning 60 minutes before the graded glucose infusion and continuing through the end of the 180-minute glucose infusion study period
Recruitment Status: RECRUITING
Sponsor: Mayo Clinic...